1.
Kadono Y, Kawaguchi S, Nohara T, Shigehara K, Izumi K, Kamijima T, Seto C, Takano A, Yotsuyanagi S, Nakagawa R, Miyagi T, Aoyama S, Asahi H, Fukuda R, Mizokami A. Favorable Response of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma with Only Small Lesions to not be Considered Measurable by RECIST. Urol J [Internet]. 2021Dec.20 [cited 2022Jun.26];19(03):202-8. Available from: https://journals.sbmu.ac.ir/urolj/index.php/uj/article/view/6652